BridgeBio Pharma Inc. announced the pricing of $550 million of convertible senior notes due 2033 in a private offering. The company granted initial purchasers an option to buy up to an additional $82.5 million of notes. Net proceeds are estimated at $538.4 million, to be used for repurchasing or settling future obligations on 2.50% convertible senior notes due 2027 and for general corporate purposes. $82.5 million in cash will be used to repurchase around 1.1 million shares of common stock. The sale of notes is expected to close on January 21, 2026, pending customary closing conditions.

Read more at Nasdaq: BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033